Extended Data Fig. 3: HER2 trispecific Ab stimulated CD8+ T cell did not inhibit cell cycle progression/proliferation in multiple HER2 expressing cancer cell lines but upregulated proinflammatory pathways.
From: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
a, The antitumor effect of HER2 trispecific Ab against multiple tumor cell lines was evaluated with human CD8+ T cells as effector cells (E:T = 5:1). Breast cancer cell lines HCC1937, HCC70, BT549 and gastric cancer cell line OE19 were used as targets. After 1 day of incubation, the tumor cell lines did not exhibit cell cycle arrest at the G1/S stage in cells that remained alive based on flow cytometry. b (left), Scatter plots of RNAs significantly upregulated (≥ 5-fold, red), or downregulated (≤ 5-fold, green), in HER2 trispecific Ab treated target cells compared to the control in presence of CD8+ effector cells. b, (right), Enrichment analysis of gene sets in tumor cells after HER2 trispecific Ab treatment compared to control in the presence of CD8+ effector cells. Red bar = upregulation.
